Madrigal Pharmaceuticals, Inc.

NasdaqGS:MDGL Stock Report

Market Cap: US$10.0b

Madrigal Pharmaceuticals Future Growth

Future criteria checks 6/6

Madrigal Pharmaceuticals is forecast to grow earnings and revenue by 54.7% and 28.5% per annum respectively. EPS is expected to grow by 54.5% per annum. Return on equity is forecast to be 48.3% in 3 years.

Key information

54.7%

Earnings growth rate

54.55%

EPS growth rate

Biotechs earnings growth22.1%
Revenue growth rate28.5%
Future return on equity48.31%
Analyst coverage

Good

Last updated20 Feb 2026

Recent future growth updates

Recent updates

Madrigal Pharmaceuticals: What To Expect With Q4 Earnings Coming Thursday

Feb 17

Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) 26% Price Boost Is Out Of Tune With Revenues

Nov 12
Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) 26% Price Boost Is Out Of Tune With Revenues

Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) 30% Price Boost Is Out Of Tune With Revenues

Aug 22
Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) 30% Price Boost Is Out Of Tune With Revenues

Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically

Aug 13
Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically

Earnings Beat: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 08
Earnings Beat: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Earnings Beat: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

May 04
Earnings Beat: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
User avatar

FDA Approval Will Expand MASH Treatment Market Reach

First FDA-approved MASH treatment and strong U.S. market launch position Madrigal Pharmaceuticals for significant revenue growth.

Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger Outlook

Feb 26

Madrigal Pharmaceuticals Rezdiffra Vies For Blockbuster Status In MASH

Jan 19

Fast Drug Launch For Madrigal Pharmaceuticals Brings Buyout Discussion

Jan 09

Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion

Nov 03

Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings

Oct 24

While Madrigal's Rezdiffra Impresses, Great Uncertainties Loom In MASH Market

Aug 08

Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long

Jun 09

Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage

Apr 24

Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge

Mar 15

Earnings and Revenue Growth Forecasts

NasdaqGS:MDGL - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20282,9428361,047N/A11
12/31/20272,148352605N/A13
12/31/20261,491-148257N/A13
12/31/2025958-288N/AN/AN/A
9/30/2025741-289-165-161N/A
6/30/2025516-282-308-307N/A
3/31/2025317-392-401-395N/A
12/31/2024180-466-462-456N/A
9/30/202477-519-438-431N/A
6/30/202415-510-456-449N/A
3/31/2024N/A-444-391-389N/A
12/31/2023N/A-374-326-324N/A
9/30/2023N/A-347-303-303N/A
6/30/2023N/A-330-277-277N/A
3/31/2023N/A-315-259-259N/A
12/31/2022N/A-295-225-225N/A
9/30/2022N/A-274-215-214N/A
6/30/2022N/A-256-201-201N/A
3/31/2022N/A-247-191-190N/A
12/31/2021N/A-242-184-184N/A
9/30/2021N/A-236-191-191N/A
6/30/2021N/A-231-193-193N/A
3/31/2021N/A-219-171-170N/A
12/31/2020N/A-202-158-158N/A
9/30/2020N/A-171-115-115N/A
6/30/2020N/A-134-79-78N/A
3/31/2020N/A-105-66-66N/A
12/31/2019N/A-84-42-42N/A
9/30/2019N/A-68N/A-36N/A
6/30/2019N/A-55N/A-30N/A
3/31/2019N/A-42N/A-23N/A
12/31/2018N/A-33N/A-26N/A
9/30/2018N/A-30N/A-25N/A
6/30/2018N/A-30N/A-25N/A
3/31/2018N/A-32N/A-27N/A
12/31/2017N/A-31N/A-22N/A
9/30/2017N/A-30N/A-22N/A
6/30/2017N/A-36N/A-26N/A
3/31/2017N/A-31N/A-21N/A
12/31/2016N/A-26N/A-18N/A
9/30/2016N/A-21N/A-13N/A
6/30/2016N/A-8N/A-5N/A
3/31/2016N/A-7N/A-3N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MDGL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.4%).

Earnings vs Market: MDGL is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MDGL is expected to become profitable in the next 3 years.

Revenue vs Market: MDGL's revenue (28.5% per year) is forecast to grow faster than the US market (10.3% per year).

High Growth Revenue: MDGL's revenue (28.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MDGL's Return on Equity is forecast to be very high in 3 years time (48.3%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/20 19:30
End of Day Share Price 2026/02/20 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Madrigal Pharmaceuticals, Inc. is covered by 28 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eliana MerleBarclays
Matthew LuchiniBMO Capital Markets Equity Research
Jason ZemanskyBofA Global Research